Modified intrapleural cisplatin treatment for lung cancer with positive pleural lavage cytology or malignant effusion
| Autor: | Takeshi Nagayasu, Satoshi Hashizume, Tadayuki Oka, Shinji Akamine, Tsutomu Tagawa, Takatomo Yamayoshi, Keitaro Matsumoto, Masafumi Morinaga, Masao Inoue, Tomayoshi Hayashi, Masashi Muraoka |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Lung Neoplasms Pleural effusion medicine.medical_treatment Antineoplastic Agents Pneumonectomy Carcinoma Non-Small-Cell Lung Cytology Carcinoma Humans Medicine Lung cancer Survival rate Aged Pleural Cavity Intraoperative Care business.industry General Medicine Middle Aged Pleural cavity medicine.disease Combined Modality Therapy Pleural Effusion Malignant Surgery Survival Rate Chest tube medicine.anatomical_structure Oncology Female Cisplatin business Bronchoalveolar Lavage Fluid |
| Zdroj: | Journal of Surgical Oncology. 93:323-329 |
| ISSN: | 1096-9098 0022-4790 |
| DOI: | 10.1002/jso.20470 |
| Popis: | Objectives We evaluate the efficacy and safety of the modified intrapleural cisplatin treatment for lung cancer patients with positive pleural lavage cytology or malignant effusion. Methods The treatment was performed for seven patients with malignant effusion and 18 patents with positive pleural lavage cytology. After pulmonary resection, the pleural cavity was filled with cisplatin with a normal saline solution for 30 min. Complications and survival of the patients were evaluated. Results The chest tube duration were significantly prolonged in the treatment (CDDP) group (5.7 ± 3.6 vs. 2.8 ± 2.6 days). We had one operative death that developed a bronchial fistula; however, the other complications were not severe. The mortality rate was 4% and the morbidity rate was 60%. We experienced two carcinomatous pleuritis in the CDDP group. The median survival time of the CDDP group was 47.0 ± 11.1 months and the 3- and 5-year survival rate was 52.6% and 11.3%, respectively. Conclusions We were able to perform this treatment for these advanced lung cancer patients, which had the preventive effect of carcinomatous pleuritis. This therapy shows the possibility of a treatment that might lead to an improvement in the prognosis of these patients, without causing severe complications. J. Surg. Oncol. 2006;93: 323–329. © 2006 Wiley-Liss, Inc. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text